Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Håkan Mellstedt

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Clinical considerations for biosimilar antibodiesHåkan Mellstedt
Cancer Immunology, Immunotherapy : CII|May 21, 2005
T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the DevilHåkan Mellstedt, Aniruddha Choudhury
Current Medical Research and Opinion|September 24, 2015
Biosimilars - terms of usePaul Declerck, Håkan Mellstedt, Silvio Danese
Clinical Lung Cancer|June 11, 2008
The future of cancer vaccines for non-small-cell lung cancer: ongoing trialsAniruddha Choudhury, Marzia Palma, Håkan Mellstedt
Lung Cancer (Amsterdam, Netherlands)|April 9, 2011
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experienceHåkan Mellstedt, Johan Vansteenkiste, Nick Thatcher
Expert Review of Vaccines|July 20, 2005
Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trialsSzilvia Mosolits, Bo Nilsson, Håkan Mellstedt
International Journal of Oncology|November 3, 2010
FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatmentBiyun Wang, Parviz Kokhaei, Håkan Mellstedt, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2007
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicityMaria Liljefors, Bo Nilsson, Håkan Mellstedt, et al.
Blood|February 11, 2003
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myelomaLotta Hansson, Hodjattallah Rabbani, Jan Fagerberg, et al.
Seminars in Oncology|May 25, 2006
Strategies in the management of alemtuzumab-related side effectsAnders Osterborg, Claes Karlsson, Jeanette Lundin, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Clinical considerations for biosimilar antibodiesHåkan Mellstedt
Cancer Immunology, Immunotherapy : CII|May 21, 2005
T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the DevilHåkan Mellstedt, Aniruddha Choudhury
Current Medical Research and Opinion|September 24, 2015
Biosimilars - terms of usePaul Declerck, Håkan Mellstedt, Silvio Danese
Clinical Lung Cancer|June 11, 2008
The future of cancer vaccines for non-small-cell lung cancer: ongoing trialsAniruddha Choudhury, Marzia Palma, Håkan Mellstedt
Lung Cancer (Amsterdam, Netherlands)|April 9, 2011
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experienceHåkan Mellstedt, Johan Vansteenkiste, Nick Thatcher
Expert Review of Vaccines|July 20, 2005
Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trialsSzilvia Mosolits, Bo Nilsson, Håkan Mellstedt
International Journal of Oncology|November 3, 2010
FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatmentBiyun Wang, Parviz Kokhaei, Håkan Mellstedt, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2007
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicityMaria Liljefors, Bo Nilsson, Håkan Mellstedt, et al.
Blood|February 11, 2003
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myelomaLotta Hansson, Hodjattallah Rabbani, Jan Fagerberg, et al.
Seminars in Oncology|May 25, 2006
Strategies in the management of alemtuzumab-related side effectsAnders Osterborg, Claes Karlsson, Jeanette Lundin, et al.
Pageof 9